NO300114B1 - Fremgangsmåte for fremstilling av et vandig suspensjonspreparat for injeksjon - Google Patents

Fremgangsmåte for fremstilling av et vandig suspensjonspreparat for injeksjon Download PDF

Info

Publication number: NO300114B1
Authority: NO; Norway
Prior art keywords: water; less; local anesthetic; insoluble; weight
Prior art date: 1990-03-20

Application number

NO923429A

Other languages

English (en)

Norwegian (no)

Other versions

NO923429L (no

NO923429D0 (no

Inventor

Eric Willem Ackerman

Rene Jacobus Elisabert Grouls

Hendrikus Hubertus Mar Korsten

Original Assignee

Catharina Ziekenhuis Stichting

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-20

Filing date

1992-09-03

Publication date

1997-04-14

1992-09-03 Application filed by Catharina Ziekenhuis Stichting filed Critical Catharina Ziekenhuis Stichting

1992-09-03 Publication of NO923429D0 publication Critical patent/NO923429D0/no

1992-09-17 Publication of NO923429L publication Critical patent/NO923429L/no

1997-04-14 Publication of NO300114B1 publication Critical patent/NO300114B1/no

Links

238000002360 preparation method Methods 0.000 title claims abstract description 22
239000007900 aqueous suspension Substances 0.000 title claims abstract description 17
238000002347 injection Methods 0.000 title claims abstract description 9
239000007924 injection Substances 0.000 title claims abstract description 9
238000004519 manufacturing process Methods 0.000 title abstract description 6
239000002245 particle Substances 0.000 claims abstract description 30
239000003589 local anesthetic agent Substances 0.000 claims abstract description 25
208000002193 Pain Diseases 0.000 claims abstract description 21
230000036407 pain Effects 0.000 claims abstract description 20
239000004084 narcotic analgesic agent Substances 0.000 claims abstract description 5
239000000725 suspension Substances 0.000 claims description 42
238000000034 method Methods 0.000 claims description 17
230000003533 narcotic effect Effects 0.000 claims description 15
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 14
229920000053 polysorbate 80 Polymers 0.000 claims description 14
239000012736 aqueous medium Substances 0.000 claims description 13
239000002736 nonionic surfactant Substances 0.000 claims description 13
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 13
229940068968 polysorbate 80 Drugs 0.000 claims description 12
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 11
239000000203 mixture Substances 0.000 claims description 11
229940124641 pain reliever Drugs 0.000 claims description 10
239000000843 powder Substances 0.000 claims description 6
229960004050 aminobenzoic acid Drugs 0.000 claims description 5
235000014113 dietary fatty acids Nutrition 0.000 claims description 5
239000000194 fatty acid Substances 0.000 claims description 5
229930195729 fatty acid Natural products 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
239000000243 solution Substances 0.000 claims description 5
150000001298 alcohols Chemical class 0.000 claims description 4
150000004665 fatty acids Chemical class 0.000 claims description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
239000012266 salt solution Substances 0.000 claims description 3
238000010257 thawing Methods 0.000 claims description 3
125000005907 alkyl ester group Chemical group 0.000 claims description 2
150000001408 amides Chemical class 0.000 claims description 2
150000002170 ethers Chemical class 0.000 claims description 2
239000008103 glucose Substances 0.000 claims description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
229920000136 polysorbate Polymers 0.000 claims description 2
229950008882 polysorbate Drugs 0.000 claims description 2
239000013543 active substance Substances 0.000 abstract description 9
238000007913 intrathecal administration Methods 0.000 abstract description 3
239000004094 surface-active agent Substances 0.000 abstract description 2
206010002091 Anaesthesia Diseases 0.000 abstract 2
230000037005 anaesthesia Effects 0.000 abstract 2
230000008595 infiltration Effects 0.000 abstract 1
238000001764 infiltration Methods 0.000 abstract 1
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 22
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
229960005181 morphine Drugs 0.000 description 11
239000003708 ampul Substances 0.000 description 9
230000000694 effects Effects 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
239000000126 substance Substances 0.000 description 8
239000002202 Polyethylene glycol Substances 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
239000003193 general anesthetic agent Substances 0.000 description 6
229960005015 local anesthetics Drugs 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 5
229940035676 analgesics Drugs 0.000 description 5
229940035674 anesthetics Drugs 0.000 description 5
239000000730 antalgic agent Substances 0.000 description 5
239000000375 suspending agent Substances 0.000 description 5
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 4
229920001214 Polysorbate 60 Polymers 0.000 description 4
210000005036 nerve Anatomy 0.000 description 4
239000002504 physiological saline solution Substances 0.000 description 4
230000001954 sterilising effect Effects 0.000 description 4
238000004659 sterilization and disinfection Methods 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
230000003444 anaesthetic effect Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
BLFLLBZGZJTVJG-UHFFFAOYSA-N ethyl ester of p-aminobenzoic acid Natural products CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
229940113124 polysorbate 60 Drugs 0.000 description 3
230000001953 sensory effect Effects 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
230000007774 longterm Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920001515 polyalkylene glycol Polymers 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
210000000273 spinal nerve root Anatomy 0.000 description 2
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
ONPGOSVDVDPBCY-CQSZACIVSA-N 6-amino-5-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-n-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridazine-3-carboxamide Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NN=1)N)=CC=1C(=O)NC(C=C1)=CC=C1C(=O)N1CCN(C)CC1 ONPGOSVDVDPBCY-CQSZACIVSA-N 0.000 description 1
206010058019 Cancer Pain Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000004404 Intractable Pain Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
229920001219 Polysorbate 40 Polymers 0.000 description 1
229920002651 Polysorbate 85 Polymers 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003470 adrenal cortex hormone Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960005274 benzocaine Drugs 0.000 description 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
229960001736 buprenorphine Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
210000001951 dura mater Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
-1 fatty acid esters Chemical class 0.000 description 1
229960002428 fentanyl Drugs 0.000 description 1
IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
150000004694 iodide salts Chemical class 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000002988 lumbosacral plexus Anatomy 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
229920000056 polyoxyethylene ether Polymers 0.000 description 1
235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
229940101027 polysorbate 40 Drugs 0.000 description 1
229940113171 polysorbate 85 Drugs 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000003594 spinal ganglia Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Oil, Petroleum & Natural Gas (AREA)
Anesthesiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

NO923429A 1990-03-20 1992-09-03 Fremgangsmåte for fremstilling av et vandig suspensjonspreparat for injeksjon NO300114B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL9000634A NL9000634A (nl)	1990-03-20	1990-03-20	Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
PCT/NL1991/000042 WO1991014455A1 (en)	1990-03-20	1991-03-20	Aqueous suspension preparation for injection, method for producing the same and use thereof for producing pain relief

Publications (3)

Publication Number	Publication Date
NO923429D0 NO923429D0 (no)	1992-09-03
NO923429L NO923429L (no)	1992-09-17
NO300114B1 true NO300114B1 (no)	1997-04-14

Family

ID=19856770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO923429A NO300114B1 (no)	1990-03-20	1992-09-03	Fremgangsmåte for fremstilling av et vandig suspensjonspreparat for injeksjon

Country Status (15)

Country	Link
US (1)	US5346903A (de)
EP (1)	EP0521070B1 (de)
JP (1)	JPH05507466A (de)
AT (1)	ATE121631T1 (de)
AU (1)	AU646857B2 (de)
BR (1)	BR1100601A (de)
CA (1)	CA2077641C (de)
DE (1)	DE69109279T2 (de)
DK (1)	DK0521070T3 (de)
ES (1)	ES2074269T3 (de)
FI (1)	FI98890C (de)
GR (1)	GR3015940T3 (de)
NL (1)	NL9000634A (de)
NO (1)	NO300114B1 (de)
WO (1)	WO1991014455A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5206267A (en) *	1991-05-09	1993-04-27	Morton Shulman	Pain controlling composition and method of preparation
US5635540A (en) *	1994-12-09	1997-06-03	The University Of Virginia Patent Foundation	Stabilized topical pharmaceutical preparations
US6077545A (en)	1995-10-30	2000-06-20	Matrix Pharmaceuticals, Inc.	Process and composition for therapeutic cisplatin (CDDP)
EA001257B1 (ru) *	1996-03-26	2000-12-25	Эли Лилли Энд Компани	Бензотиофены, содержащие их фармацевтические композиции и способы лечения патологических состояний с их использованием
US6835194B2 (en) *	1999-03-18	2004-12-28	Durect Corporation	Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6541021B1 (en) *	1999-03-18	2003-04-01	Durect Corporation	Devices and methods for pain management
US7074803B2 (en) *	2001-03-02	2006-07-11	Durect Corporation	Opioid formulations
EP1389121B1 (de)	2001-04-24	2012-02-22	Purdue Research Foundation	Verfahren und zusammensetzungen zur behandlung von nervengewebeverletzungen in säugetieren
US20030181426A1 (en) *	2002-02-11	2003-09-25	Eisenach James C.	Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
US7838034B2 (en)	2002-07-30	2010-11-23	Grunenthal Gmbh	Intravenous pharmaceutical form of administration
DE10234784A1 (de) *	2002-07-30	2004-02-19	Günenthal GmbH	Intravenös applizierbare, pharmazeutische Darreichungsform
US20040102476A1 (en) *	2002-11-25	2004-05-27	Chan Tai Wah	High concentration formulations of opioids and opioid derivatives
JP2006523609A (ja) *	2002-12-31	2006-10-19	アルタスファーマシューティカルズインコーポレイテッド	タンパク質結晶およびイオン性ポリマーの複合体
RU2357750C2 (ru) *	2002-12-31	2009-06-10	Элтус Фармасьютикалз Инк.	Кристаллы человеческого гормона роста и способы их получения
GB0300531D0 (en)	2003-01-10	2003-02-12	West Pharm Serv Drug Res Ltd	Pharmaceutical compositions
US20090023629A1 (en) *	2005-12-23	2009-01-22	Altus Pharmaceuticals Inc.	Compositions comprising polycation-complexed protein crystals and methods of treatment using them
CA2672284C (en) *	2006-12-18	2014-08-26	Altus Pharmaceuticals Inc.	Human growth hormone formulations
FI20075091A0 (fi) *	2007-02-09	2007-02-09	Kim Lemberg	Noroksimorfoni käytettäväksi lääkeaineena
WO2008106571A2 (en) *	2007-02-28	2008-09-04	Abbott Laboratories	Sustained release parenteral formulations of buprenorphine
US9125867B2 (en) *	2010-02-24	2015-09-08	Invincible Biotechnology	Diversion- and/or abuse-resistant compositions and methods for making the same
GB2513060B (en) *	2010-06-08	2015-01-07	Rb Pharmaceuticals Ltd	Microparticle buprenorphine suspension
US9272044B2 (en)	2010-06-08	2016-03-01	Indivior Uk Limited	Injectable flowable composition buprenorphine
GB201404139D0 (en)	2014-03-10	2014-04-23	Rb Pharmaceuticals Ltd	Sustained release buprenorphine solution formulations
CA3015557C (en)	2014-11-07	2019-07-16	Indivior Uk Limited	The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
US10646484B2 (en)	2017-06-16	2020-05-12	Indivior Uk Limited	Methods to treat opioid use disorder
WO2021073548A1 (zh) *	2019-10-16	2021-04-22	广东东阳光药业有限公司	一种药物组合物
WO2022175977A1 (en) *	2021-02-18	2022-08-25	Navin Saxena Research And Technology Private Limited	A biodegradable implant composition and process for long term delivery of buprenorphine and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB784659A (en) *	1954-11-26	1957-10-16	Upjohn Co	Therapeutic compositions and aqueous suspensions thereof
US3337406A (en) *	1963-12-12	1967-08-22	Mar Sal Inc	Treatment of arteriosclerotic diseases
EP0031603A1 (de) *	1979-12-31	1981-07-08	American Cyanamid Company	Pharmazeutische Zusammensetzung eines Grundstoffs
US4963367A (en) *	1984-04-27	1990-10-16	Medaphore, Inc.	Drug delivery compositions and methods
US4599354A (en) *	1985-03-11	1986-07-08	Morton Shulman	Composition and method for producing prolonged pain relief

1990
- 1990-03-20 NL NL9000634A patent/NL9000634A/nl not_active Application Discontinuation
1991
- 1991-03-20 DK DK91906827.0T patent/DK0521070T3/da active
- 1991-03-20 EP EP91906827A patent/EP0521070B1/de not_active Expired - Lifetime
- 1991-03-20 AU AU75580/91A patent/AU646857B2/en not_active Ceased
- 1991-03-20 DE DE69109279T patent/DE69109279T2/de not_active Expired - Fee Related
- 1991-03-20 AT AT91906827T patent/ATE121631T1/de not_active IP Right Cessation
- 1991-03-20 ES ES91906827T patent/ES2074269T3/es not_active Expired - Lifetime
- 1991-03-20 WO PCT/NL1991/000042 patent/WO1991014455A1/en not_active Ceased
- 1991-03-20 CA CA002077641A patent/CA2077641C/en not_active Expired - Fee Related
- 1991-03-20 JP JP91507032A patent/JPH05507466A/ja active Pending
1992
- 1992-09-03 NO NO923429A patent/NO300114B1/no unknown
- 1992-09-08 FI FI924019A patent/FI98890C/fi not_active IP Right Cessation
- 1992-11-20 US US07/979,128 patent/US5346903A/en not_active Expired - Lifetime
1995
- 1995-04-27 GR GR950400877T patent/GR3015940T3/el unknown
1997
- 1997-05-13 BR BR1100601-3A patent/BR1100601A/pt active IP Right Grant

Also Published As

Publication number	Publication date
ATE121631T1 (de)	1995-05-15
CA2077641A1 (en)	1991-09-21
JPH05507466A (ja)	1993-10-28
NL9000634A (nl)	1991-10-16
WO1991014455A1 (en)	1991-10-03
ES2074269T3 (es)	1995-09-01
CA2077641C (en)	2001-07-03
FI924019L (fi)	1992-09-08
NO923429L (no)	1992-09-17
BR1100601A (pt)	2000-04-18
US5346903A (en)	1994-09-13
EP0521070B1 (de)	1995-04-26
GR3015940T3 (en)	1995-07-31
DE69109279T2 (de)	1995-11-09
FI98890B (fi)	1997-05-30
FI924019A0 (fi)	1992-09-08
AU7558091A (en)	1991-10-21
AU646857B2 (en)	1994-03-10
DE69109279D1 (de)	1995-06-01
FI98890C (fi)	1997-09-10
EP0521070A1 (de)	1993-01-07
DK0521070T3 (da)	1995-05-22
NO923429D0 (no)	1992-09-03

Publication	Publication Date	Title
NO300114B1 (no)	1997-04-14	Fremgangsmåte for fremstilling av et vandig suspensjonspreparat for injeksjon
JP3067806B2 (ja)	2000-07-24	プロポフォールとエデテートとを含有する水中油滴エマルジョン
JP2003535884A (ja)	2003-12-02	プロポフォールの改善された注射可能な分散物
AU6159600A (en)	2001-03-05	Moxifloxacin formulation containing common salt
US9241922B2 (en)	2016-01-26	Pharmaceutical solution of taxanes comprising pH regulator and preparation method thereof
EP0824916B1 (de)	2000-10-11	Ein organisches aminenthaltende pranoprofen-augentropfen
UA73954C2 (uk)	2005-10-17	Водний розчин для внутрішньовенного введення та фармацевтичний розчин, що містять левосимендан
US5709883A (en)	1998-01-20	Long acting narcotic analgesics and antagonists
CN114344299A (zh)	2022-04-15	一种具有长效缓释作用的脂质释药系统及其制备方法
JPH064534B2 (ja)	1994-01-19	長期間の疼痛緩和をもたらす配合剤
KR20220120766A (ko)	2022-08-31	파모티딘 함유 즉시 사용형 주사용액
WO1997011681A1 (en)	1997-04-03	Sustained release delivery system and long acting narcotic analgesics and antagonists
JP2529055B2 (ja)	1996-08-28	苦痛抑制組成物及び調製法
TW202504607A (zh)	2025-02-01	羅哌卡因或其藥學上可接受的鹽的組合物及其用途
JP4472175B2 (ja)	2010-06-02	プロスタグランジンおよびベンジルアルコールを含む液剤
EP0694300A1 (de)	1996-01-31	Behandlung von Impotenz
ES et al.	0	AQUEOUS SUSPENSION PREPARATION FOR INJECTION, METHOD FOR PRODUCING THE SAME AND USE THEREOF FOR PRODUCING PAIN RELIEF.
JP2002541087A (ja)	2002-12-03	防腐添加剤を含有するプロポフォール組成物
Payá et al.	2022	AS-OCT of cyclitic membrane pre and post treatment with rtPA in the anterior chamber
GB1564454A (en)	1980-04-10	Antiglaucomatous ophtalmic solution
CA2896793A1 (en)	2014-07-24	Formulations of albu-bche, preparation and uses thereof
CN105663105B (zh)	2017-03-22	一种双氯芬酸钠利多卡因复方注射剂组合物及其制备方法
EP0656777B1 (de)	1997-01-29	Spritzfertige azosemid-injektionslösungen
CA1098039A (en)	1981-03-24	Intravenous solutions with antimicrobial agent
CN1177922A (zh)	1998-04-01	含2,6－二异丙基苯酚和乙二胺四乙酸盐的水包油型乳液